Richard A. Larson to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications Richard A. Larson has written about Clinical Trials, Phase II as Topic.
Connection Strength
0.388
-
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood. 2010 Oct 07; 116(14):2420-8.
Score: 0.087
-
Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine. Semin Oncol. 2007 Dec; 34(6 Suppl 5):S13-20.
Score: 0.073
-
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005 Oct 01; 104(7):1442-52.
Score: 0.063
-
Current use and future development of gemtuzumab ozogamicin. Semin Hematol. 2001 Jul; 38(3 Suppl 6):24-31.
Score: 0.047
-
Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1367-79, x.
Score: 0.045
-
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Cancer. 2016 07 15; 122(14):2178-85.
Score: 0.033
-
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006 Jan 20; 24(3):437-43.
Score: 0.016
-
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001 Oct 01; 61(19):7233-9.
Score: 0.012
-
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol. 2000 Mar; 18(6):1301-8.
Score: 0.011